Neuraxis highlights pediatric post-concussion clinical study

Carmel, ind., aug. 29, 2023 (globe newswire) -- neuraxis, inc. (“neuraxis,” or the “company”) (nyse american: nrxs), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted a prospective study on the effect of auricular percutaneous electrical nerve field stimulation (penfs™) in patients with post-concussion syndrome (pcs), a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ib-stim™ in children with post-concussion symptoms.
NRXS Ratings Summary
NRXS Quant Ranking